Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective pilot study

Current Drug Targets

Volumn 18, Issue 7, 2017, Pages 772-785

  Gragnani, Laura ^a   Piluso, Alessia ^a   Urraro, Teresa ^a   Fabbrizzi, Alessio ^a   Fognani, Elisa ^a   Petraccia, Luisa ^a   Genovesi, Alessandro ^a   Giubilei, Lidia ^a   Ranieri, Jessica ^a   Stasi, Cristina ^a   Monti, Monica ^a   Zignego, Anna Linda ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antiviral treatment; Direct acting antiviral (DAA); Efficacy; HCV; Interferon free (IFN free); Mixed cryoglobulinemia; Safety

Indexed keywords

ABT-267; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; RITONAVIR; VIRUS RNA;

AGED; CHRONIC HEPATITIS C; COMPLICATION; CRYOGLOBULINEMIA; DRUG EFFECTS; FEMALE; GENETICS; HEPACIVIRUS; HUMAN; MALE; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

AGED; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; CRYOGLOBULINEMIA; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME;

EID: 85020275293     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450117666160208145432     Document Type: Review

References (92)

1. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991; 9(6): 621-4.
2. Zignego AL, Gragnani L, Piluso A, et al. Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol 2015; 11(1): 15-31.
3. Zignego AL, Gragnani L, Giannini C, Laffi G. The hepatitis C virus infection as a systemic disease. Intern Emerg Med 2012; 7 Suppl 3: S201-8.
4. Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol 2012; 2012: 980942.
5. Ferri C, La Civita L, Longombardo G, et al. Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma. Clin Exp Rheumatol 1994; 12(1): 89-90.
6. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46S5: S165-73.
7. Bellentani S, Miglioli L, Masutti F, Saccoccio G, Tiribelli C. Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery. Microbes Infect 2000; 2(14): 1757-63.
8. Craxi A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008; 29(1-2): 85-95.
9. De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011; 70(7): 1183-90.
10. Quartuccio L, Isola M, Corazza L, et al. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol 2012; 30(1 Suppl 70): S48-52.
11. Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011; 10(8): 444-54.
12. Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81(5): 1132-6.
13. Marcellin P, Descamps V, Martinot-Peignoux M, et al. Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology 1993; 104(1): 272-7.
14. Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008; 12(3): 611-36, ix.
15. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39(1): 2-17.
16. Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007; 13(17): 2467-78.
17. Giannini C, Giannelli F, Zignego A. Association between mixed cryoglobulinemia, translocation (14; 18), and persistence of occult HCV lymphoid infection after treatment. Hepatology 2006; 43(5): 1166-7.
18. Giannini C, Petrarca A, Monti M, et al. Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood 2008; 111(5): 2943-5.
19. Ferri C, Zignego AL, Longombardo G, et al. Effect of alphainterferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients. Infection 1993; 21(2): 93-7.
20. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328(7): 465-70.
21. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330(11): 751-6.
22. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84(10): 3336-43.
23. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virusassociated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46(6): 1700-4.
24. Mazzaro C, Pozzato G, Moretti M, et al. Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia [published erratum appears in Haematologica 1994; 79(5): 486]. Haematologica 1994; 79(4): 342-9.
25. Gilli P, Stabellini N, Storari A, Gualandi G, Guerra G, Ghinelli F. Effect of human leukocyte alpha interferon on cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Nephrol Dial Transplant 1996; 11(3): 526-8.
26. Mazzaro C, Lacchin T, Moretti M, et al. Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 (Suppl 13): S181-5.
27. Migliaresi S, Tirri G. Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 (Suppl 13): S175-80.
28. Yamabe H, Johnson RJ, Gretch DR, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995; 25(1): 67-9.
29. Casaril M, Capra F, Gabrielli GB, et al. Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alpha therapy. J Interferon Cytokine Res 1996; 16(8): 585-8.
30. Cohen P, Nguyen QT, Deny P, et al. Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. Ann Med Interne (Paris) 1996; 147(2): 81-6.
31. Adinolfi LE, Utili R, Zampino R, Ragone E, Mormone G, Ruggiero G. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. Eur J Gastroenterol Hepatol 1997; 9(11): 1067-72.
32. Sarac E, Bastacky S, Johnson JP. Response to high-dose interferonalpha after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 1997; 30(1): 113-5.
33. Zuber M, Gause A. Peripheral neuropathy during interferon-alpha therapy in patients with cryoglobulinemia and hepatitis virus infection. J Rheumatol 1997; 24(12): 2488-9.
34. Akriviadis EA, Xanthakis I, Navrozidou C, Papadopoulos A. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha. J Clin Gastroenterol 1997; 25(4): 612-8.
35. Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90(10): 3865-73.
36. Mazzaro C, Carniello GS, Colle R, et al. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy. Ital J Gastroenterol Hepatol 1997; 29(4): 343-50.
37. Donada C, Crucitti A, Donadon V, Chemello L, Alberti A. Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 1998; 92(8): 2983-4.
38. Durand JM, Cacoub P, Lunel-Fabiani F, et al. Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 1998; 25(6): 1115-7.
39. Calleja JL, Albillos A, Moreno-Otero R, et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 1999; 13(9): 1179-86.
40. Cresta P, Musset L, Cacoub P, et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999; 45(1): 122-8.
41. Misiani R, Bellavita P, Baio P, et al. Successful treatment of HCVassociated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrol Dial Transplant 1999; 14(6): 1558-60.
42. Mazzaro C, Panarello G, Carniello S, et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 2000; 32(8): 708-15.
43. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27(9): 2172-8.
44. Garini G, Allegri L, Carnevali L, Catellani W, Manganelli P, Buzio C. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001; 38(6): E35.
45. Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001; 28(11): 2466-73.
46. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002; 81(5): 398-409.
47. Cacoub P, Lidove O, Maisonobe T, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002; 46(12): 3317-26.
48. Casato M, Mecucci C, Agnello V, et al. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood 2002; 99(6): 2259-61.
49. Loustaud-Ratti V, Liozon E, Karaaslan H, et al. Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med 2002; 113(6): 516-9.
50. Sikaneta T, Williams WW, Chung RT, Cosimi AB, Pascual AM. Remission of hepatitis C virus-associated cryoglobulinemic glomerulonephritis with interferon alfa-2b and ribavirin combination therapy after liver transplantation. Transplantation 2002; 74(12): 1767-8.
51. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis Cassociated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18(8): 1573-80.
52. Mazzaro C, Zorat F, Comar C, et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 2003; 30(8): 1775-81.
53. Rossi P, Bertani T, Baio P, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63(6): 2236-41.
54. Alric L, Plaisier E, Thebault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43(4): 617-23.
55. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005; 52(3): 911-5.
56. Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42(5): 632-8.
57. Vigani AG, Macedo-de-Oliveira A, Pavan MH, Pedro MN, Goncales Jr FL. Hepatitis C virus infection, cryoglobulinemia, and peripheral neuropathy: a case report. Braz J Med Biol Res 2005; 38(12): 1729-34.
58. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006; 54(11): 3696-706.
59. Garini G, Allegri L, Lannuzzella F, Vaglio A, Buzio C. HCVrelated cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 2007; 78(1): 51-9.
60. Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colledan M, Strazzabosco M. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007; 41(2): 216-20.
61. Joshi S, Kuczynski M, Heathcote EJ. Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia. Dig Dis Sci 2007; 52(9): 2410-7.
62. Koziolek MJ, Scheel A, Bramlage C, Groene HJ, Mueller GA, Strutz F. Effective treatment of hepatitis C-associated immunecomplex nephritis with cryoprecipitate apheresis and antiviral therapy. Clin Nephrol 2007; 67(4): 245-9.
63. Trebst C, Wedemeyer H, Manns MP, Tillmann H, Windhagen A. Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. Eur J Gastroenterol Hepatol 2007; 19(1): 91-2.
64. Landau DA, Rosenzwajg M, Saadoun D, Trebeden-Negre H, Klatzmann D, Cacoub P. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum 2008; 58(9): 2897-907.
65. Mazzaro C, Monti G, Saccardo F, et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol 2011; 29(6): 933-41.
66. Gragnani L, Fognani E, Piluso A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. Hepatology 2014 Nov 27.
67. Gragnani L, Fabbrizzi A, Triboli E, et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. Dig Liver Dis 2014; 46(9): 833-7.
68. Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med 2015; 127(4): 413-7.
69. Stine JG, Cornella S, Shah NL. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann Rheum Dis 2014; 73(10): e64.
70. De Nicola S, Aghemo A, Campise MR, et al. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. Antivir Ther 2014; 19(5): 527-31.
71. Saadoun D, Resche Rigon M, Pol S, et al. Peg-IFNalpha Ribavirin/Protease inhibitor combination in severe hepatitis C virus associated mixed cryoglobulinemia vasculitis. J Hepatol 2015; 62(1): 24-30
72. Saadoun D, Cacoub P. HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al. Ann Rheum Dis 2014; 73(9): e59.
73. Zimmermann R, Konig V, Bauditz J, Hopf U. Interferon alfa in leukocytoclastic vasculitis, mixed cryoglobulinaemia, and chronic hepatitis C. Lancet 1993; 341(8844): 561-2.
74. Bojic I, Lilic D, Radojcic C, Mijuskovic P. Deterioration of mixed cryoglobulinemia during treatment with interferon-alpha-2a. J Gastroenterol 1994; 29(3): 369-71.
75. Harle JR, Disdier P, Pelletier J, et al. Dramatic worsening of hepatitis C virus-related cryoglobulinemia subsequent to treatment with interferon alfa. JAMA 1995; 274(2): 126.
76. Gordon AC, Edgar JD, Finch RG. Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia. J Infect 1998; 36(2): 229-30.
77. Scelsa SN, Herskovitz S, Reichler B. Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia. Muscle Nerve 1998; 21(11): 1526-9.
78. Cid MC, Hernandez-Rodriguez J, Robert J, et al. Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum 1999; 42(5): 1051-5.
79. Friedman G, Mehta S, Sherker AH. Fatal exacerbation of hepatitis C-related cryoglobulinemia with interferon-alpha therapy. Dig Dis Sci 1999; 44(7): 1364-5.
80. Batisse D, Karmochkine M, Jacquot C, Kazatchkine MD, Weiss L. Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. Eur J Gastroenterol Hepatol 2004; 16(7): 701-3.
81. Parise ER, de Oliveira AC, Ferraz ML, Pereira AB, Leite KR. Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin. Rev Inst Med Trop Sao Paulo 2007; 49(2): 67-72.
82. De Blasi T, Aguilar Marucco D, Cariti G, Maiello A, De Rosa FG, Di Perri G. Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b. Infection 2008; 36(3): 285-7.
83. Levine JW, Gota C, Fessler BJ, Calabrese LH, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005; 32(6): 1164-7.
84. Landau DA, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008; 58(2): 604-11.
85. Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014; 73(5): 831-7.
86. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368(20): 1878-87.
87. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2014[April 24, 2014].
88. Monti G, Saccardo F, Pioltelli P, Rinaldi G. The natural history of cryoglobulinemia: symptoms at onset and during follow-up. A report by the Italian Group for the Study of Cryoglobulinemias (GISC). Clin Exp Rheumatol 1995; 13 (Suppl): S129-33.
89. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002; 55(1): 4-13.
90. Zignego AL, Giannelli F, Marrocchi ME, et al. T(14; 18) translocation in chronic hepatitis C virus infection. Hepatology 2000; 31(2): 474-9.
91. Zignego AL, Ferri C, Giannini C, et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996; 124(1 Pt 1): 31-4.
92. Nelson D, Yoshida EM, Paulson MS, et al. Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor. Antivir Ther 2014; 19(7): 679-86.